CO5251405A1 - 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida - Google Patents

2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida

Info

Publication number
CO5251405A1
CO5251405A1 CO00090625A CO00090625A CO5251405A1 CO 5251405 A1 CO5251405 A1 CO 5251405A1 CO 00090625 A CO00090625 A CO 00090625A CO 00090625 A CO00090625 A CO 00090625A CO 5251405 A1 CO5251405 A1 CO 5251405A1
Authority
CO
Colombia
Prior art keywords
compound
formula
isobutiramida
tolil
trifluorometil
Prior art date
Application number
CO00090625A
Other languages
English (en)
Spanish (es)
Inventor
Theresa Maria Ballard
Guy Andrew Higgins
Torsten Hoffmann
Sonia Maria Poli
Andrew Sleight
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5251405A1 publication Critical patent/CO5251405A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CO00090625A 1999-11-29 2000-11-27 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida CO5251405A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
CO5251405A1 true CO5251405A1 (es) 2003-02-28

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00090625A CO5251405A1 (es) 1999-11-29 2000-11-27 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida

Country Status (49)

Country Link
EP (1) EP1103545B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3480835B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100390117B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1152016C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR033659A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE253561T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU775292B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG64622B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0005616B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2326529C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5251405A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ299286B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE60006340T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1103545T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2000000106A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA004404B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2208205T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2801590A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2356863A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GC (1) GC0000151A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20022763B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT200000197A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20000809A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU224703B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID28483A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL139868A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2212B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1320120B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO2298B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA26754A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA00011672A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY127426A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO317264B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ508386A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA11513A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PA (1) PA8507201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20010901A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL195957B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1103545E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG97171A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1103545T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK285373B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SV (1) SV2002000227A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TNSN00226A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200302077T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA70326C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY26458A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU73400A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200006964B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
KR100514236B1 (ko) * 1999-02-24 2005-09-13 에프. 호프만-라 로슈 아게 페닐 유도체 및 피리디닐 유도체
CN1178917C (zh) * 2000-07-14 2004-12-08 弗·哈夫曼-拉罗切有限公司 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
RU2004126440A (ru) * 2002-01-31 2005-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Генетические полиморфизмы гена препротахикинина
MXPA06000192A (es) 2003-07-03 2006-04-11 Hoffmann La Roche Antagonistas duales del receptor nk1/nk3 para el tratamiento esquizofrenia.
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
EP1776342B1 (en) 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
CA2602445C (en) * 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
JP5523706B2 (ja) * 2005-09-23 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 新規投薬配合物
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
JP5806420B1 (ja) 2013-11-08 2015-11-10 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
SG11201510135XA (en) 2014-02-07 2016-01-28 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0533280T4 (da) * 1991-09-20 2005-02-28 Glaxo Group Ltd Ny medicinsk anvendelse af tachykininantagonister
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69434991T2 (de) * 1993-12-29 2008-03-06 Merck Sharp & Dohme Ltd., Hoddesdon Substituierte Morpholinderivate und ihre Verwendung als Arzneimittel
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0733632B1 (en) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
CN1178917C (zh) * 2000-07-14 2004-12-08 弗·哈夫曼-拉罗切有限公司 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
PL195957B1 (pl) 2007-11-30
UY26458A1 (es) 2001-05-31
BG104992A (en) 2001-11-30
BRPI0005616B8 (pt) 2021-07-06
SI1103545T1 (en) 2004-02-29
IL139868A0 (en) 2002-02-10
TNSN00226A1 (fr) 2002-05-30
EP1103545B1 (en) 2003-11-05
AR033659A1 (es) 2004-01-07
GB0028566D0 (en) 2001-01-10
NO317264B1 (no) 2004-09-27
CZ299286B6 (cs) 2008-06-04
GB2356863A (en) 2001-06-06
TR200302077T4 (tr) 2004-01-21
CZ20004399A3 (cs) 2001-07-11
OA11513A (fr) 2004-02-03
JO2298B1 (en) 2005-09-12
IS2212B (is) 2007-02-15
FR2801590A1 (fr) 2001-06-01
SV2002000227A (es) 2002-02-05
SK17932000A3 (sk) 2001-11-06
BG64622B1 (bg) 2005-09-30
PT1103545E (pt) 2004-03-31
CA2326529C (en) 2009-12-22
CA2326529A1 (en) 2001-05-29
IT1320120B1 (it) 2003-11-18
EA200001114A2 (ru) 2001-08-27
JP2001151754A (ja) 2001-06-05
NZ508386A (en) 2003-02-28
ATE253561T1 (de) 2003-11-15
HRP20000809A2 (en) 2001-12-31
AU775292B2 (en) 2004-07-29
IS5725A (is) 2001-05-29
ZA200006964B (en) 2001-06-05
HUP0004725A2 (hu) 2002-04-29
PA8507201A1 (es) 2002-02-21
EP1103545A1 (en) 2001-05-30
SG97171A1 (en) 2003-07-18
EA004404B1 (ru) 2004-04-29
ES2208205T3 (es) 2004-06-16
PL344147A1 (en) 2001-06-04
IL139868A (en) 2009-09-01
NO20006012L (no) 2001-05-30
UA70326C2 (en) 2004-10-15
HU0004725D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-02-28
MY127426A (en) 2006-11-30
JP3480835B2 (ja) 2003-12-22
GT200000197A (es) 2002-05-22
ID28483A (id) 2001-05-31
ES2171134A1 (es) 2002-08-16
DOP2000000106A (es) 2002-07-30
BRPI0005616B1 (pt) 2017-12-12
CN1297888A (zh) 2001-06-06
DE10058310A1 (de) 2001-05-31
HU224703B1 (en) 2006-01-30
DE60006340D1 (de) 2003-12-11
MXPA00011672A (es) 2002-08-20
YU73400A (sh) 2003-02-28
KR20010051983A (ko) 2001-06-25
HK1036759A1 (en) 2002-01-18
DK1103545T3 (da) 2004-03-15
EA200001114A3 (ru) 2001-12-24
ITMI20002575A1 (it) 2002-05-29
GEP20022763B (en) 2002-08-26
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
BR0005616A (pt) 2001-07-17
NO20006012D0 (no) 2000-11-28
PE20010901A1 (es) 2001-09-20
SK285373B6 (sk) 2006-12-07
AU7178700A (en) 2001-05-31
MA26754A1 (fr) 2004-12-20
CN1152016C (zh) 2004-06-02
KR100390117B1 (ko) 2003-07-04

Similar Documents

Publication Publication Date Title
CO5251405A1 (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida
CO5271657A1 (es) Derivados de azaindol
CO5150238A1 (es) Polimorfos de telmisartan, procedimiento para su preparacion y su empleo para la preparacion de un medicamento
CO5460265A1 (es) Compuestos quimicos
CO5251404A1 (es) Compuestos antibioticos de azalida
CO5160253A1 (es) Complejo de 1,4-benzodiazepinas sustituidas y sulfobutileter -7-ciclodextrina o 2-hidroxipropil-b-ciclodextrina .
EA200101194A1 (ru) Производные 4,5,6,7-тетрагидроиндазола в качестве противоопухолевых средств
CO5261585A1 (es) Nueva forma cristalina del acido n-[4-[2-(2-amino-4,7- dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil] benzoil]-l-glutamico y procedimiento para su preparacion
CA2398682A1 (en) Phosphonium and imidazolium salts and methods of their preparation
CO5200785A1 (es) Uso terapeutico de quinazolina
CO5200832A1 (es) Derivados de acidos heterociclicos, o una sal farmaceuticamente aceptable de los mismos, que son agentes antidiabeticos y antiobesidad
PE20021059A1 (es) Compuestos de triazol utiles en el tramiento de enfermedades asociadas con la actividad no deseada de citoquinas
CO5271735A1 (es) Forma cristalina
SE0004245D0 (sv) Novel compounds and their use
BR0109048A (pt) Processo para a sìntese de citalopram
CO5180605A1 (es) Compuestos de indol
EP1189900A4 (en) HETEROCYCLIC AMINOPYRROLIDINE DERIVATIVES FOR USE AS MELATONERGIC AGENTS
CO5090837A1 (es) Derivados de 1,3,4-oxadiazolona
CO5160260A1 (es) Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
CO5200762A1 (es) Preparacion de piperidin-4-onas sustituidas
AR050709A1 (es) Metodo para preparar irbesartan e intermediarios del mismo
CA2362217A1 (en) Process for preparing phenylpyrazole pesticidal intermediates
CO5221101A1 (es) Composiciones y metodos para reprimir insectos que deterioran cultivos de arroz y otros
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
CO5160328A1 (es) Derivados de etan sulfonil-piperidina

Legal Events

Date Code Title Description
FG Application granted